A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)‐Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer

LESSONS LEARNED: Concurrent ETBX‐011, ETBX‐051, and ETBX‐061 can be safely administered to patients with advanced cancer. All patients developed CD4(+) and/or CD8(+) T‐cell responses after vaccination to at least one tumor‐associated antigen (TAA) encoded by the vaccine; 5/6 patients (83%) developed...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncologist
Autores principales: Gatti‐Mays, Margaret E., Redman, Jason M., Donahue, Renee N., Palena, Claudia, Madan, Ravi A., Karzai, Fatima, Bilusic, Marijo, Sater, Houssein Abdul, Marté, Jennifer L., Cordes, Lisa M., McMahon, Sheri, Steinberg, Seth M., Orpia, Alanvin, Burmeister, Andrea, Schlom, Jeffrey, Gulley, James L., Strauss, Julius
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Clinical Trial Results
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7288633/
https://ncbi.nlm.nih.gov/pubmed/31594913
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0608
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares